Tender

Services to deliver Onasemnogene abeparvovec/Zolgensma

NHS ARDEN AND GREATER EAST MIDLANDS COMMISSIONING SUPPORT UNIT

This public procurement record has 1 release in its history.

Tender

02 Feb 2021 at 14:00

Tender Notice
Summary of the contracting process

NHS Arden and Greater East Midlands Commissioning Support Unit is facilitating a tender process for the provision of services to deliver Onasemnogene abeparvovec/Zolgensma, a gene therapy aimed at treating spinal muscular atrophy (SMA). This procurement falls within the health and social work services industry category and is set to conclude the tender period on 8th March 2021, with contract execution anticipated to start on 30th April 2021 and last through to 29th April 2025. The total contract value is estimated at £6 million, with a minimum bid value of £2.5 million. Interested providers must navigate an open procurement process.

This tender presents significant growth opportunities for businesses specialising in health services, particularly those with expertise in gene therapies and treatment for rare conditions. Companies that can demonstrate a strong neuromuscular multidisciplinary team and the ability to manage containment level 1 product delivery will find themselves well-positioned to compete. Additionally, providers must cooperate closely with Novartis Gene Therapies to ensure compliance with their guidelines and are encouraged to engage in preliminary discussions before submitting their proposals.

Find more tenders on our Open Data Platform.
How relevant is this notice?

Notice Information

Notice Title

Services to deliver Onasemnogene abeparvovec/Zolgensma

Notice Description

Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabling production of sufficient amounts of SMN. It is administered intravenously. NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor. As well as having a neuromuscular MDT and experience in treating children with SMA, the successful providers will need to have the capability to safely manage the product itself in line with it being classified as 'containment level 1' and ensure that all elements of the patient pathway (pre-treatment, during treatment and post-treatment) can be put into place. The providers will also be expected to operate as a national-MDT to ensure that eligible patients can be treated within appropriate timescales. It is anticipated that the number of children requiring treatment each year is between 25 and 35, although this number may be subject to change, depending on the outcome of the NICE evaluation and, for example, if new-born screening for SMA was introduced. Novartis Gene Therapies is the company who produce this gene therapy and providers will be required to comply with the company's contractual documentation. This is currently in draft so providers will be expected to have contacted Novartis Gene Therapies prior to submitting a tender response to discuss their requirements in respect of providing a service to deliver Onasemnogene abeparvovec/Zolgensma. Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has made its recommendation. To do so would risk the NHS not being ready to provide access within the timeframe set out in the Mandate requirements on NICE approved treatments and not being able to make the treatment available as soon as possible after the NICE decision has been made. Providers are therefore submitting bids to deliver a service 'at risk' and it may be the case that the product does not receive a positive NICE recommendation. Bidders are responsible for their own costs incurred throughout each stage of the Procurement process.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-b5fd17-7eae1ca1-9b8d-44b1-922b-e9940b4db374
Publication Source
Contracts Finder
Latest Notice
https://www.contractsfinder.service.gov.uk/Notice/884abb56-80f3-400c-b548-180d1abad56e
Current Stage
Tender
All Stages
Tender

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services

CPV Codes

85000000 - Health and social work services

85100000 - Health services

85140000 - Miscellaneous health services

Notice Value(s)

Tender Value
£6,000,000 £1M-£10M
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
2 Feb 20215 years ago
Submission Deadline
8 Mar 2021Expired
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
29 Apr 2021 - 29 Apr 2025 4-5 years
Recurrence
Not specified

Notice Status

Tender Status
Active
Lots Status
Not Specified
Awards Status
Not Specified
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS ARDEN AND GREATER EAST MIDLANDS COMMISSIONING SUPPORT UNIT
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 6LH
Post Town
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI44 Lewisham and Southwark
Delivery Location
Not specified
Local Authority
Southwark
Electoral Ward
St George's
Westminster Constituency
Bermondsey and Old Southwark

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts. 

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-b5fd17-7eae1ca1-9b8d-44b1-922b-e9940b4db374-2021-02-02T14:00:35Z",
    "date": "2021-02-02T14:00:35Z",
    "ocid": "ocds-b5fd17-7eae1ca1-9b8d-44b1-922b-e9940b4db374",
    "language": "en",
    "initiationType": "tender",
    "tender": {
        "id": "20210202140031-68205",
        "title": "Services to deliver Onasemnogene abeparvovec/Zolgensma",
        "description": "Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabling production of sufficient amounts of SMN. It is administered intravenously. NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor. As well as having a neuromuscular MDT and experience in treating children with SMA, the successful providers will need to have the capability to safely manage the product itself in line with it being classified as 'containment level 1' and ensure that all elements of the patient pathway (pre-treatment, during treatment and post-treatment) can be put into place. The providers will also be expected to operate as a national-MDT to ensure that eligible patients can be treated within appropriate timescales. It is anticipated that the number of children requiring treatment each year is between 25 and 35, although this number may be subject to change, depending on the outcome of the NICE evaluation and, for example, if new-born screening for SMA was introduced. Novartis Gene Therapies is the company who produce this gene therapy and providers will be required to comply with the company's contractual documentation. This is currently in draft so providers will be expected to have contacted Novartis Gene Therapies prior to submitting a tender response to discuss their requirements in respect of providing a service to deliver Onasemnogene abeparvovec/Zolgensma. Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has made its recommendation. To do so would risk the NHS not being ready to provide access within the timeframe set out in the Mandate requirements on NICE approved treatments and not being able to make the treatment available as soon as possible after the NICE decision has been made. Providers are therefore submitting bids to deliver a service 'at risk' and it may be the case that the product does not receive a positive NICE recommendation. Bidders are responsible for their own costs incurred throughout each stage of the Procurement process.",
        "datePublished": "2021-02-02T14:00:35Z",
        "status": "active",
        "classification": {
            "scheme": "CPV",
            "id": "85000000",
            "description": "Health and social work services"
        },
        "additionalClassifications": [
            {
                "scheme": "CPV",
                "id": "85100000",
                "description": "Health services"
            },
            {
                "scheme": "CPV",
                "id": "85140000",
                "description": "Miscellaneous health services"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "countryName": "British Oversea Territories"
                    },
                    {
                        "countryName": "Channel Islands"
                    },
                    {
                        "countryName": "Europe"
                    },
                    {
                        "countryName": "Isle of Man"
                    },
                    {
                        "countryName": "Rest of the World"
                    },
                    {
                        "countryName": "United Kingdom"
                    }
                ]
            }
        ],
        "minValue": {
            "amount": 2500000,
            "currency": "GBP"
        },
        "value": {
            "amount": 6000000,
            "currency": "GBP"
        },
        "procurementMethod": "open",
        "procurementMethodDetails": "Open procedure",
        "tenderPeriod": {
            "endDate": "2021-03-08T12:00:00Z"
        },
        "contractPeriod": {
            "startDate": "2021-04-30T00:00:00+01:00",
            "endDate": "2025-04-29T23:59:59+01:00"
        },
        "suitability": {
            "sme": false,
            "vcse": false
        },
        "mainProcurementCategory": "services",
        "documents": [
            {
                "id": "1",
                "documentType": "tenderNotice",
                "description": "Opportunity notice on Contracts Finder",
                "url": "https://www.contractsfinder.service.gov.uk/Notice/884abb56-80f3-400c-b548-180d1abad56e",
                "datePublished": "2021-02-02T14:00:35Z",
                "format": "text/html",
                "language": "en"
            },
            {
                "id": "2",
                "documentType": "Link",
                "description": "Additional data",
                "url": "https://uk.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=36403&B=AGCSU"
            },
            {
                "id": "3",
                "documentType": "Link",
                "description": "User / Company",
                "url": "https://uk.eu-supply.com/ctm/Company/CompanyInformation/Index/68205"
            }
        ]
    },
    "parties": [
        {
            "id": "GB-CFS-161602",
            "name": "NHS Arden and Greater East Midlands Commissioning Support Unit",
            "identifier": {
                "legalName": "NHS Arden and Greater East Midlands Commissioning Support Unit"
            },
            "address": {
                "streetAddress": "80 London Road",
                "locality": "London",
                "postalCode": "SE1 6LH",
                "countryName": "ENG"
            },
            "contactPoint": {
                "name": "Anna Salt",
                "email": "anna.salt@nhs.net"
            },
            "details": {
                "url": "http://www.england.nhs.uk"
            },
            "roles": [
                "buyer"
            ]
        }
    ],
    "buyer": {
        "id": "GB-CFS-161602",
        "name": "NHS Arden and Greater East Midlands Commissioning Support Unit"
    }
}